Thyroid cancer is a growth of abnormal cells in the thyroid, the butterfly-shaped gland at the base of your neck that controls your metabolism, heart rate, and body temperature. It’s one of the most treatable cancers: the overall five-year survival rate is 98.3%, and an estimated 45,240 new cases will be diagnosed in the United States in 2026. That said, outcomes vary dramatically depending on the type, so understanding the basics matters.
The Four Main Types
Your thyroid contains two kinds of hormone-producing cells. Follicular cells make thyroid hormone, which regulates how your body uses energy. Parafollicular C cells make calcitonin, a hormone involved in calcium balance. Which cell turns cancerous determines the type of thyroid cancer you have and, to a large extent, how it behaves.
Papillary thyroid cancer is by far the most common, accounting for 70% to 80% of all cases. It originates in follicular cells and tends to grow slowly. The five-year survival rate across all stages is above 99%. Even when it has spread to nearby lymph nodes, survival remains at 99%.
Follicular thyroid cancer makes up about 10% to 15% of cases. It also arises from follicular cells and carries a five-year survival rate of 98% overall. It’s somewhat more likely than papillary cancer to spread to distant organs like the lungs or bones, but it’s still considered highly treatable.
Medullary thyroid cancer originates in the parafollicular C cells and accounts for roughly 2% of thyroid cancers. Its overall five-year survival rate is 93%, though that drops to 50% when the cancer has spread to distant sites. Some cases are hereditary, linked to inherited genetic mutations that can be identified through blood testing of family members.
Anaplastic thyroid cancer is the rarest form, found in less than 2% of patients, and the most aggressive. It grows and spreads rapidly. The five-year survival rate is 10% overall, and just 5% when distant metastases are present. Unlike the other types, it often resists standard treatments.
Symptoms and Warning Signs
Most thyroid cancers don’t cause symptoms in the early stages. The first sign is usually a painless lump or nodule in the front of your neck that you or your doctor notice during a routine exam. As the tumor grows, it can press on nearby structures and cause more noticeable problems:
- A lump in the front of the neck, sometimes growing quickly
- Swelling in the neck
- Pain in the front of the neck, sometimes radiating up to the ears
- Hoarseness or voice changes that don’t go away
- Difficulty swallowing or breathing
- A persistent cough not related to a cold
- A lump or lumps on the side of the neck, which can indicate spread to lymph nodes
It’s worth knowing that thyroid nodules are extremely common and the vast majority are not cancerous. Still, any new or growing lump in the neck deserves evaluation.
What Causes Thyroid Cancer
The single strongest known risk factor is radiation exposure to the head and neck area, particularly during childhood. The risk begins to rise at relatively low radiation doses and increases in a roughly linear fashion with higher doses. After the Chernobyl nuclear accident, researchers found a striking increase in thyroid cancer among children in contaminated areas, with specific genetic rearrangements in their tumor cells that were directly tied to radiation damage.
Other factors that increase risk include a family history of thyroid cancer or certain inherited genetic syndromes, being female (women are diagnosed about three times more often than men), and a history of goiter or other thyroid conditions. For medullary thyroid cancer specifically, inherited mutations in a gene called RET can be passed from parent to child and significantly raise lifetime risk.
How Thyroid Cancer Is Diagnosed
Diagnosis typically starts with a physical exam and a neck ultrasound. The ultrasound gives your doctor detailed information about any nodules: their size, shape, borders, and whether they have features that look suspicious, such as irregular edges, internal calcifications, or unusual blood flow patterns.
If a nodule looks concerning, the next step is a fine-needle aspiration biopsy, usually guided by ultrasound. A thin needle is inserted into the nodule to collect a small sample of cells. Those cells are then examined under a microscope and classified using a six-tier system called the Bethesda scale, which ranges from benign (category II) to malignant (category VI). Categories in the middle, III and IV, represent indeterminate results where the cells look somewhat abnormal but aren’t clearly cancerous. These “gray zone” results sometimes require repeat biopsy, molecular testing, or surgery to reach a definitive answer.
Your doctor will also consider your personal risk profile: family history of thyroid cancer, any prior radiation therapy to the neck, how quickly the nodule is growing, and your thyroid hormone levels.
How Staging Works
Thyroid cancer staging is unusual compared to most other cancers because your age at diagnosis plays a central role. Under the current staging system, the age cutoff is 55. If you’re younger than 55, you’re classified as stage I regardless of tumor size, lymph node involvement, or whether the cancer has grown into surrounding tissue. The only exception is if the cancer has spread to distant organs, which bumps you to stage II. This reflects the reality that younger patients with differentiated thyroid cancer have an excellent prognosis even with locally advanced disease.
For patients 55 and older, staging accounts more heavily for tumor size, the degree of spread to lymph nodes, and whether distant metastases are present. The most advanced stage for differentiated thyroid cancer in older patients involves distant metastases. Anaplastic thyroid cancer is staged differently: it is automatically considered at least stage IV at diagnosis because of its aggressive behavior.
Treatment
Surgery is the primary treatment for nearly all thyroid cancers. For smaller, low-risk tumors, a surgeon may remove only the lobe of the thyroid containing the cancer. For larger tumors or those with higher-risk features, a total thyroidectomy (removal of the entire gland) is standard. The surgery itself typically requires a one- to two-day hospital stay, with most people returning to normal activities within a couple of weeks.
After total thyroidectomy for papillary or follicular cancer, some patients receive radioactive iodine therapy. You swallow a capsule or liquid containing a radioactive form of iodine, which is selectively absorbed by any remaining thyroid cells, including microscopic cancer cells the surgeon couldn’t see. This treatment is generally recommended for patients with larger tumors, cancer that has grown beyond the thyroid capsule, or cancer that has spread to lymph nodes or distant sites. For very small, low-risk tumors confined to the thyroid, radioactive iodine usually isn’t necessary.
Medullary and anaplastic thyroid cancers don’t respond to radioactive iodine because they arise from cell types that don’t absorb iodine the same way. These cancers rely on surgery and, in some cases, targeted drug therapies or external radiation.
Life After Treatment
If your entire thyroid is removed, your body can no longer produce thyroid hormone on its own. You’ll take a daily thyroid hormone replacement pill for the rest of your life. For thyroid cancer patients specifically, the dose is often set intentionally higher than what you’d need for simple hormone replacement. The goal is to suppress a pituitary signal called TSH that can stimulate any remaining thyroid cancer cells to grow. Your doctor will adjust the dose over time based on blood tests and your cancer’s risk profile.
Most people feel normal on hormone replacement once the right dose is found, though it can take a few months of adjustments. Some people experience symptoms of slightly elevated thyroid hormone levels, like a faster heartbeat or feeling jittery, because of the higher doses used for cancer suppression. Regular blood work and periodic neck ultrasounds become part of your long-term monitoring routine, typically continuing for years after treatment.
Survival by Type and Stage
The prognosis for most thyroid cancer patients is excellent, but the numbers vary significantly by type. Based on data from patients diagnosed between 2015 and 2021:
Papillary cancer has a five-year survival rate above 99% for localized and regional disease, dropping to 71% when it has spread to distant organs. Follicular cancer follows a similar pattern: above 99% for localized disease, 97% for regional, and 62% for distant. Medullary cancer carries slightly lower rates: above 99% localized, 94% regional, and 50% distant.
Anaplastic cancer stands apart entirely. Even when confined to the thyroid (localized), the five-year survival rate is 45%. When it has spread regionally, that falls to 14%, and distant disease carries a 5% survival rate. The overall five-year survival for anaplastic thyroid cancer is 10%. This type accounts for a disproportionate share of thyroid cancer deaths despite making up less than 2% of cases.